Close Menu

NEW YORK – Roche announced Friday its uPath PD-L1 (SP263) automated digital pathology algorithm for non-small cell lung cancer received the CE-IVD mark.

The algorithm uses artificial intelligence to offer one-click objective and reproducible automated assessments of scanned slide images that can help with diagnosis and targeted treatment options, the company said in a statement. It highlights positively and negatively stained tumor cells to determine if tumors are positive for the PD-L1 biomarker.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.